Key points from article :
NHS estimates just under 90 people in England will be eligible for the treatment.
People with a mutation of the RPE65 gene will be suitable for the new treatment.
In the short term, Luxturna improves vision and prevents the condition from getting worse.
Treatment will become available after NICE expects will publish its final guidance, from January 2020.
